NanoRepro AG

NanoRepro AG maintains a strong liquidity position with a current ratio of 49.94, indicating that its current assets significantly exceed its current liabilities. The company holds €9,098,120 in cash and equivalents, and it has no long-term debt, which supports its liquidity profile. However, the company's free cash flow is negative at -€2,377,530, suggesting that capital expenditures and other operational costs are outpacing cash inflows. The company's profitability is currently negative, with a return on equity of -5.36% and a return on assets of -5.24%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating income is negative at -€3,623,830, and the net income is also negative at -€2,045,760, reflecting ongoing operational challenges. NanoRepro AG's revenue is primarily derived from its diagnostic test products, including OvuQUICK, GraviQUICK, and MenoQUICK. The company's geographic exposure is concentrated in Germany, and it does not disclose significant international operations. The company's revenue concentration in a single country may expose it to local economic and regulatory risks. The company's growth trajectory is uncertain, as it has not provided specific revenue growth projections for the current or next fiscal year. The lack of detailed growth guidance makes it difficult to assess the company's future performance. However, the company's operating cash flow is positive at €9,860,300, which suggests that it is generating cash from its operations despite its negative net income. The risk assessment for NanoRepro AG indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and its capital structure is free of long-term debt. However, the company's negative net income and operating income suggest that it may face financial challenges in the future. The dilution potential is also low, as the number of basic and diluted shares outstanding is the same. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's recent financial performance and lack of detailed growth guidance suggest that it is in a development phase, focusing on research and product development rather than immediate profitability.